Worldwide,<unk>  is the most common opportunistic infection among people with HIV infection. In addition to its frequency,<unk>  is also associated with substantial morbidity and mortality. Despite the complexities of treating two infections requiring multidrug therapy at the same time, antiretroviral therapy can be life-saving among patients with<unk>  and advanced HIV disease. Observational studies in a variety of settings have shown that use of antiretroviral therapy during<unk>  treatment results in marked decreases in the risk of death or other opportunistic infections among persons with<unk>  and advanced HIV disease.
Concomitant use of treatment for<unk>  and antiretroviral therapy is complicated by the adherence challenge of polypharmacy, overlapping side effect profiles of antituberculosis<unk> s and antiretroviral<unk> s, immune reconstitution inflammatory syndrome, and<unk> -drug<unk> s.  The key<unk> s, and the focus of this chapter, are those between the rifamycin antibiotics and four classes of antiretroviral<unk> s: Protease inhibitors, Nucleoside reverse transcriptase inhibitors (NRTI), CCR5-inhibitors, and integrase inhibitor 
Only two of the currently available antiretroviral<unk>  classes, the nucleoside analogues (other than zidovudine) and enfuvirtide (a parenteral entry inhibitor) do not have significant<unk> s with the rifamycins.
HIV and tuberculosis coinfection : drug interaction
Bubonic plague/primary prevention
HIV AIDS secondary prevention
Cardiac diseases in AIDS prevention
Malaria future or investigational therapies
Leprosy tertiary prevention
HIV associated nephropathy prevention
HIV opportunistic infection pneumocystis pneumonia: prevention and treatment guidelines